A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2016
Price : $35 *
At a glance
- Drugs MORAb 066 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Morphotek
- 28 Sep 2016 Status changed from active, no longer recruiting to completed.
- 24 Feb 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2016 as per ClinicalTrials.gov record.
- 15 Feb 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.